

USSN Not yet assigned FUCHSS
Page 1 of 13

## Appendix AP20 RESULTING 24 MAR 2006

## Claim Amendments

## 1. (Currently amended) Compounds A compound of formula I

in which

R1 is hydrogen or 1-4C-alkyl,

R2 is hydrogen, halogen, hydroxyl, nitro, amino, 1-7Ctrifluoromethyl, 3-7C-cycloalkyl, 3-7Calkyl, cycloalkyl-1-4C-alkyl, 1-4C-alkoxy, completely or predominantly fluorine-substituted 1-4C-alkoxy, 1-4Calkoxy-1-4C-alkyl, 1-4C-alkoxy-1-4C-alkoxy, 1-4Calkoxycarbonyl, mono- or di-1-4C-alkylaminocarbonyl, monodi-1-4C-alkylaminosulfonyl, or 1-4Calkylcarbonylamino, 1-4C-alkylsulfonylamino, phenyl, R21- and/or R211-substituted phenyl, phenyl-1-4C-alkyl, phenyl-1-4C-alkyl wherein the phenyl moiety substituted by R22, phenyl-1-4C-alkoxy, pyridyl, pyridyl substituted by R23, pyridyl-1-4C-alkyl, or pyridyl-1-4C-

alkyl wherein the pyridyl moiety is substituted by R24, in which

- is cyano, halogen, carboxyl, 1-4C-alkyl, 1-4C-alkoxy, aminocarbonyl, mono- or di-1-4C-alkylaminocarbonyl, 1-4C-alkylcarbonylamino, 1-4C-alkoxycarbonyl, aminosulfonyl, mono- or di-1-4C-alkylaminosulfonyl, amino, mono- or di-1-4C-alkylamino, trifluoromethyl, hydroxyl, phenylsulfonylamino, phenyl-1-4C-alkoxy, or -S(O)<sub>2</sub>-Het, in which
- Het is bonded to the adjacent sulfonyl group via a ring nitrogen atom, and is a 3- to 7-membered fully saturated heterocyclic ring comprising one nitrogen atom, to which the sulfonyl group is attached, and optionally one further heteroatom selected from the group consisting of N(R210), oxygen and sulfur, in which
- R210 is 1-4C-alkyl,
- R211 is halogen or 1-4C-alkoxy,
- R22 is halogen, 1-4C-alkyl or 1-4C-alkoxy,
- R23 is halogen, 1-4C-alkyl or 1-4C-alkoxy,
- R24 is halogen, 1-4C-alkyl or 1-4C-alkoxy,
- R3 is hydrogen, halogen, 1-4C-alkyl or 1-4C-alkoxy,
- R4 is 1-4C-alkyl, or 1-4C-alkoxy,

and the salts, the N-oxides and the salts of the N-oxides of these compounds or a salt, N-oxide or a salt of an N-oxide thereof.

- 2. (Currently amended) Compounds The compound of formula I as claimed in claim 1 in which
- R1 is hydrogen or 1-2C-alkyl,
- R2 is hydrogen, halogen, phenyl, or R21- and/or R211- substituted phenyl, in which
- R21 is 1-4C-alkyl, cyano, halogen, mono- or di-1-4C-alkylamino, trifluoromethyl, mono- or di-1-4C-alkylaminosulfonyl, hydroxyl, phenyl-1-4C-alkoxy, or - $S(O)_2$ -Het, in which
- Het is azetidin-1-yl, pyrrolidin-1-yl, piperidin-1-yl, or 4N-(R210)-piperazin-1-yl, in which

R210 is 1-4C-alkyl,

R211 is halogen,

R3 is hydrogen,

R4 is methyl, or methoxy,

- 3. (Currently amended) Compounds The compound of formula I as claimed in claim 1 in which
- R1 is hydrogen, methyl or ethyl,
- R2 is hydrogen, iodine, bromine, phenyl, or R21- and/or R211-substituted phenyl, in which
- R21 is methyl, cyano, chlorine, fluorine, dimethylamino, trifluoromethyl, dimethylaminosulfonyl, hydroxyl, benzyloxy, or  $-S(O)_2$ -Het, in which
- Het is azetidin-1-yl, pyrrolidin-1-yl, piperidin-1-yl, or 4N-methyl-piperazin-1-yl, in which

R211 is chlorine,

R3 is hydrogen,

R4 is methyl, or methoxy,

- **4.** (Currently amended) Compounds The compound of formula I as claimed in claim 1 in which
- R1 is hydrogen or methyl,
- R2 is bonded in the 6-position of the 3H-imidazo[4,5-b]pyridine ring, and is hydrogen, iodine, bromine,

- phenyl, 3-hydroxyl-phenyl, 4-(R21)-phenyl, or 3,5-dichloro-phenyl, in which
- R21 is methyl, cyano, chlorine, fluorine, dimethylamino, trifluoromethyl, dimethylaminosulfonyl, benzyloxy, or  $S(0)_2$ -Het, in which
- Het is azetidin-1-yl, pyrrolidin-1-yl, piperidin-1-yl, or 4N-methyl-piperazin-1-yl, in which
- R3 is hydrogen,
- R4 is methyl, or methoxy, and the salts, the N-oxides and the salts of the N-oxides

of these compounds or a salt, N-oxide or a salt of an N-

oxide thereof.

- 5. (Currently amended) Compounds The compound of formula I as claimed in claim 1 in which
- R1 is hydrogen or 1-4C-alkyl,
- R2 is hydrogen, halogen, hydroxyl, nitro, amino, 1-7C-alkyl, trifluoromethyl, 3-7C-cycloalkyl, 3-7C-cycloalkyl-1-4C-alkyl, 1-4C-alkoxy, completely or predominantly fluorine-substituted 1-4C-alkoxy, 1-4C-alkoxy-1-4C-alkyl, 1-4C-alkoxy-1-4C-alkoxy, 1-4C-alkoxycarbonyl, mono- or di-1-4C-alkylaminocarbonyl, mono- or di-1-4C-alkylaminosulfonyl, 1-4C-alkylaminosulfonyl, 1-4C

alkylcarbonylamino, 1-4C-alkylsulfonylamino, phenyl, R21- and/or R211-substituted phenyl, phenyl-1-4C-alkyl, phenyl-1-4C-alkyl wherein the phenyl moiety is substituted by R22, phenyl-1-4C-alkoxy, pyridyl, pyridyl substituted by R23, pyridyl-1-4C-alkyl, pyridyl-1-4C-alkyl wherein the pyridyl moiety is substituted by R24, in which

R21 is cyano, halogen, carboxyl, 1-4C-alkyl, 1-4C-alkoxy, aminocarbonyl, mono- or di-1-4C-alkylaminocarbonyl, 1-4C-alkylcarbonylamino, 1-4C-alkoxycarbonyl, aminosulfonyl, mono- or di-1-4C-alkylaminosulfonyl, amino, mono- or di-1-4C-alkylamino, trifluoromethyl, hydroxyl, phenylsulfonylamino or phenyl-1-4C-alkoxy,

R211 is halogen or 1-4C-alkoxy,

R22 is halogen, 1-4C-alkyl or 1-4C-alkoxy,

R23 is halogen, 1-4C-alkyl or 1-4C-alkoxy,

R24 is halogen, 1-4C-alkyl or 1-4C-alkoxy,

R3 is hydrogen, halogen, 1-4C-alkyl or 1-4C-alkoxy,

R4 is 1-4C-alkyl,

- 6. (Currently amended) Compounds A compound of formula I as claimed in claim 1 in which
- R1 is hydrogen, methyl or ethyl,
- R2 is hydrogen, iodine, bromine, phenyl, or R21-substituted phenyl, in which
- R21 is methyl, cyano, chlorine, fluorine, dimethylamino or trifluoromethyl,
- R3 is hydrogen,
- R4 is methyl,

- 7. (Currently amended) Compounds A compound of formula I as claimed in claim 1 in which
- R1 is hydrogen or methyl,
- R2 is R21-substituted phenyl, in which
- R21 is aminosulphonyl, mono- or di-1-4C-alkylaminosulfonyl, or  $-S(0)_2$ -Het, in which
- Het is azetidin-1-yl, pyrrolidin-1-yl, piperidin-1-yl, or 4N-(1-4C-alkyl)-piperazin-1-yl,
- R3 is hydrogen,
- R4 is methyl, or methoxy,

and the salts, the N-oxides and the salts of the N-oxides of these compounds or a salt, N-oxide or a salt of an N-oxide thereof.

8. (Currently amended) Compounds A compound of formula I as claimed in claim 1 which are from is of formula Ia

in which

R1 is hydrogen,

R4 is methyl or methoxy, and

A is 6-(4-dimethylaminosulphonyl-phenyl)-3H-imidazo[4,5-b]pyridin-2-yl, 6-(4-diethylaminosulphonyl-phenyl)-3H-imidazo[4,5-b]pyridin-2-yl, 6-(4-methylaminosulphonyl-phenyl)-3H-imidazo[4,5-b]pyridin-2-yl, 6-(4-aminosulphonyl-phenyl)-3H-imidazo[4,5-b]pyridin-2-yl, 6-(4-ethylaminosulphonyl-phenyl)-3H-imidazo[4,5-b]pyridin-2-yl, 6-[4-(azetidine-1-sulfonyl)-phenyl]-3H-imidazo[4,5-b]pyridin-2-yl, 6-[4-(pyrrolidine-1-sulfonyl)-phenyl]-3H-imidazo[4,5-b]pyridin-2-yl, 6-[4-(pyrrolidine-1-sulfonyl)-phenyl]-3H-imidazo[4,5-b]pyridin-2-yl, 6-[4-(pyrrolidine-1-sulfonyl)-phenyl]-3H-imidazo[4,5-b]pyridin-2-yl, 6-[4-(pyrrolidine-1-sulfonyl)-phenyl]-3H-imidazo[4,5-b]

b]pyridin-2-yl, or 6-[4-(4-methyl-piperazine-1-sulfonyl)-phenyl]-3H-imidazo[4,5-b]pyridin-2-yl,

and the salts, the N-oxides and the salts of the N-oxides

of these compounds or a salt, N-oxide or a salt of an N-oxide thereof.

- 9. (Currently amended) Compounds The compound of formula I according to any of the preceding claims claim 1 comprising one or more of the following:
- R1 is hydrogen,
- R2 is bonded to the 6-position of the 3H-imidazo[4,5-b]pyridine ring,
- R3 is hydrogen, and
- R4 is methyl;

- 10. (Currently amended) [[A]] The compound according to claim 1 which is selected from the group consisting of:
- 1. 2-[2-(2-Amino-4-methylpyridin-6-yl)ethyl]-3H-imidazo[4,5-b]pyridine

- 2. (R,S)-2-[3-(2-Amino-4-methylpyridin-6-yl)prop-2-yl]-3H-imidazo[4,5-b]pyridine
- 3. (R,S)-2-[4-(2-Amino-4-methylpyridin-6-yl)but-2-yl]-3H-imidazo[4,5-b]pyridine
- 4. 2-[2-(2-Amino-4-methylpyridin-6-yl)ethyl]-6-bromo-3H-imidazo[4,5-b]pyridine
- 5. 2-[2-(2-Amino-4-methylpyridin-6-yl)ethyl]-6-phenyl-3H-imidazo[4,5-b]pyridine
- 6. 2-[2-(2-Amino-4-methylpyridin-6-yl)ethyl]-6-(4-cyano-phenyl)-3H-imidazo[4,5-b]pyridine
- 7. 2-[2-(2-Amino-4-methylpyridin-6-yl)ethyl]-6-p-tolyl-3H-imidazo[4,5-b]pyridine
- 8. 2-[2-(2-Amino-4-methylpyridin-6-yl)ethyl]-6-(4-fluoro-phenyl)-3H-imidazo[4,5-b]pyridine
- 9. 2-[2-(2-Amino-4-methylpyridin-6-yl)ethyl]-6-(4-dimethylamino-phenyl)-3H-imidazo[4,5-b]pyridine
- 10. 2-[2-(2-Amino-4-methylpyridin-6-yl)ethyl]-6-(4-chloro-phenyl)-3H-imidazo[4,5-b]pyridine
- 11. 2-[2-(2-Amino-4-methylpyridin-6-yl)ethyl]-6-(4-iodo-phenyl)-3H-imidazo[4,5-b]pyridine
- 12. 2-[2-(2-Amino-4-methylpyridin-6-yl)ethyl]-6-(4-trifluoromethyl-phenyl)-3H-imidazo[4,5-b]pyridine

- 13. 6-{2-[6-(3-Benzyloxy-phenyl)-3H-imidazo[4,5-b]pyridin-2-yl-ethyl}-4-methyl-pyridin-2-ylamine
- 14. 6-{2-[6-(3,5-Dichloro-phenyl)-3H-imidazo[4,5-b]pyridin-2-yl]-ethyl}-4-methyl-pyridin-2-ylamine
- 15. 6-{2-[6-(4-Benzyloxy-phenyl)-3H-imidazo[4,5-b]pyridin-2-yl]-ethyl}-4-methyl-pyridin-2-ylamine
- 16. 3-{2-[2-(6-Amino-4-methyl-pyridin-2-yl)-ethyl]-3H-imidazo[4,5-b]pyridin-6-yl}-phenol
- 17. 6-(2-{6-[4-(Azetidine-1-sulfonyl)-phenyl}-3Himidazo[4,5-b]pyridin-2-yl}-ethyl)-4-methyl-pyridin-2ylamine
- 18. 4-Methyl-6-(2-{6-[4-(pyrrolidine-1-sulfonyl)-phenyl]3H-imidazo[4,5-b]pyridin-2-yl}-ethyl)-pyridin-2-ylamine
- 19. 4-Methyl-6-(2-{6-[4-(piperidine-1-sulfonyl)-phenyl]-3H-imidazo[4,5-b]pyridin-2-yl}-ethyl)-pyridin-2-ylamine
- 20. 4-{2-[2-(6-Amino-4-methyl-pyridin-2-yl)-ethyl]-3H-imidazo[4,5-b]pyridin-6-yl}-N,N-dimethyl-benzenesulfonamide
- 21. 4-Methyl-6-(2-{6-[4-(4-methyl-piperazine-1-sulfonyl)-phenyl]-3H-imidazo[4,5-b]pyridin-2-yl}-ethyl)-pyridin-2-ylamine [[, and]]
- 22. 2-[2-(2-Amino-4-methoxypyridin-6-yl)ethyl]-3H-imidazo[4,5-b]pyridine[[;]]

and the salts, N-oxides and the salts of the N-oxides thereof or a salt, N-oxide or a salt of a N-oxide thereof.

11. (Currently amended) Pharmaceutical compositions A pharmaceutical composition containing one or more compounds of formula I according to claim 1, or a salt, N-oxide or a salt of an N-oxide thereof, together with the usual pharmaceutical auxiliaries and/or excipients a pharmaceutically suitable auxiliary and/or excipient.

## **12. - 13.** (Canceled)

- 14. (Currently amended) A method for treating <u>an</u> acute inflammatory <u>disease</u> diseases in a patient comprising administering to said patient a therapeutically effective amount of a compound of formula I according to claim 1, or a salt, N-oxide or a salt of an N-oxide thereof.
- 15. (Currently amended) A method for treating <u>a</u> chronic inflammatory <u>disease</u> diseases of peripheral organs and the <u>central nervous system (CNS)</u> in a patient comprising administering to said patient a therapeutically effective amount of a compound of formula I according to claim 1, or

USSN Not yet assigned FUCHSS
Page 13 of 13

<u>a pharmaceutically acceptable salt, N-oxide or a salt of an N-oxide thereof.</u>